News

– Advancing Preparation for Phase III Clinical Trial and Accelerating Global Expansion –

Human Life CORD Japan Inc. (Head Office: Chuo-ku, Tokyo; President & CEO: Masamitsu Harata; hereinafter “HLC”), a company pioneering the practical application and global deployment of umbilical cord–derived mesenchymal stromal cells (UC-MSCs) as regenerative medicine products, has raised a total of 1.57 billion yen in its Series C Second Close.
This additional financing was completed through FUNDINNO PLUS+, a qualified-investor platform operated by FUNDINNO Inc., Japan’s leading equity crowdfunding company.

The fundraising reflects strong investor confidence in HLC’s UC-MSC-based global ecosystem business model and its advancing clinical development programs.
With the newly raised capital, HLC will reinforce its development framework for the company’s lead pipeline program — a Phase III clinical trial for Noninfectious pulmonary complications (NIPCs) following hematopoietic stem-cell transplantation — and accelerate the establishment of a global UC-MSC manufacturing and supply network to realize the earliest possible commercialization of UC-MSC-based regenerative therapies.

Masamitsu Harata, President and CEO of Human Life CORD Japan Inc., commented:

“Guided by our vision of realizing a co-creative society, we have advanced hand-in-hand with many partners who share our mission.
I sincerely appreciate the trust of the new angel investors who have joined us in this journey.
The patient-money entrusted to us through this financing is a profound symbol of confidence — and also a reminder of our responsibility.
We will continue striving to deliver a sustainable, umbilical-cord-derived cell therapy to society, bringing hope to patients suffering from rare and intractable diseases such as post-transplant idiopathic pneumonia syndrome.
Our mission is to connect as many lives as possible to the future, as swiftly as possible.”

 
About FUNDINNO PLUS+
FUNDINNO PLUS+ is a service operated by FUNDINNO Inc., which also runs Japan’s first equity-based crowdfunding platform “FUNDINNO.”
It enables qualified investors registered with FUNDINNO to invest directly in promising unlisted companies.
For more information, please visit;
https://fundinno.com/plus/plus_projects/view_h6u8mznx

[Press Release PDF] Human Life CORD Raises 1.57 Billion Yen in Series C Second Close

 
[Contact for Media Inquiries]
Public Relations, Human Life CORD Japan Inc.
Attn: Yuki Hayashi
TEL: +81-80-4671-0405
Email: info@humanlifecord.com